Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)

Welsh, Kerry J.; Baumblatt, Jane; Chege, Wambui; Goud, Ravi; Nair, Narayan

doi:10.1016/j.vaccine.2021.04.054

Cited by 131 publications

(158 citation statements)

References 9 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…A case series study of thrombocytopenia, including immune thrombocytopenia, after the receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS), reported a thrombocytopenia rate of 0.80 per million doses for Pfizer and Moderna vaccines. Based on an annual incidence rate of 3.3 ITP cases per 100,000 adults, the observed number of all thrombocytopenia cases, which included ITP, following administration of mRNA COVID-19 vaccines was not greater than the number of ITP cases expected [84]. A review of reports of 20 cases of thrombocytopenia following mRNA SARS-CoV-2 vaccination also suggests that the rate of newly diagnosed ITP is similar to the baseline incidence of ITP [85].…”

Section: Covid-19 Vaccination and Autoimmune Cytopeniamentioning

confidence: 91%

SARS-CoV-2 and Autoimmune Cytopenia

Quinn

Murakhovskaya

2021

Hemato

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a variety of clinical manifestations related to viral tissue damage, as well as a virally induced immune response. Hyperstimulation of the immune system can serve as a trigger for autoimmunity. Several immune-mediated manifestations have been described in the course of SARS-CoV-2 infection. Immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) are the most common hematologic autoimmune disorders seen in the course of SARS-CoV-2 infection. Vaccine-induced thrombocytopenia is a unique autoimmune hematologic cytopenia associated with SARS-CoV-2 vaccination. This paper will review the current literature on the association of SARS-CoV-2 infection and vaccination with autoimmune cytopenias and the clinical course of autoimmune cytopenias in patients with COVID-19.

show abstract

Section: Covid-19 Vaccination and Autoimmune Cytopeniamentioning

confidence: 91%

SARS-CoV-2 and Autoimmune Cytopenia

Quinn

Murakhovskaya

2021

Hemato

View full text Add to dashboard Cite

show abstract

“…Furthermore, in a recent study, the FDA evaluated the incidence of thrombocytopenia, including immune thrombocytopenia after mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). 9 The reporting rates of thrombocytopenia were equal to 0.80 per million doses for both mRNA vaccines, suggesting a possible coincidental onset not attributable to the mRNA vaccine. As the authors also highlight, it should be said that VAERS is a passive safety surveillance system that is operator-dependent and that can underestimate the entity of thrombocytopenic episodes.…”

Section: Case #3mentioning

confidence: 93%

Immune thrombocytopenic purpura cases following COVID-19 vaccination.

Condorelli

Markovic²,

Sciortino³

et al. 2021

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

show abstract

“…There have also been some cases of thrombocytopenia after the mRNA vaccines from Pfizer and Moderna (Lee et al, 2021;Julian et al, 2021), while others found no excess in cases of immune thrombocytopenia (Simpson et al, 2021;Welsh et al, 2021). As thrombocytopenia is rare, it is not clear if this represents the natural occurrence of thrombocytopenia or is related to the vaccine.…”

Section: Vaccine-related Thrombosismentioning

confidence: 99%

Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis

Cox

2021

Front. Pharmacol.

View full text Add to dashboard Cite

It is clear that COVID-19 is more than a pneumonia and is associated with a coagulopathy and multi-organ failure. While the use of anti-coagulants does reduce the incidence of pulmonary emboli, it does not help with survival. This suggests that the coagulopathy is more likely to be platelet-driven rather than thrombin-driven. There is significant evidence to suggest that SARS-CoV-2 virions directly interact with platelets to trigger activation leading to thrombocytopenia and thrombosis. I propose a model of multiple interactions between SARS-CoV-2 and platelets that has many similarities to that with Staphylococcus aureus and Dengue virus. As platelet activation and thrombosis are major factors in poor prognosis, therapeutics that target the platelet-SARS-CoV-2 interaction have potential in treating COVID-19 and other virus infections.

show abstract

Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS)

Cited by 131 publications

References 9 publications

SARS-CoV-2 and Autoimmune Cytopenia

SARS-CoV-2 and Autoimmune Cytopenia

Immune thrombocytopenic purpura cases following COVID-19 vaccination.

Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis

Contact Info

Product

Resources

About